Akashi Therapeutics
Tracy, along with her husband Benjamin Seckler, M.D., established Charley’s fund in 2004. Charley’s fund is a dynamic foundation focused on supporting the development of new treatments for DMD. Over the past decade, Charley’s Fund has directed $22 million to the advancement of new therapies to help find a cure for their son, Charley and many thousands of children like him. Under Tracy’s tireless efforts, Charley’s fund has invested in many promising biotech opportunities, including companies such as Sarepta, Prosensa, and PTC Therapeutics. Tracy has served as the executive director of the foundation since its inception. Tracy earned an AB from Harvard College and an MEd from Columbia University.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
Akashi Therapeutics
Akashi Therapeutics is a clinical stage biotechnology company developing a portfolio of products for Duchenne muscular dystrophy and other rare diseases.